Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease ...

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...

The European Commission (EC) has conditionally approved Ipsen’s Iqirvo (elafibranor) for the treatment of primary biliary ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...

Kayfanda (odevixibat) is labelled in the EU to treat cholestatic pruritus – itching caused by impaired bile formation or flow ...

Targeting Hepatic Lipid Accumulation Hepatic lipid accumulation is a key driver of MASLD pathogenesis. Therapeutic strategies ...

9月11日，上海交通大学医学院附属瑞金医院王卫庆、王计秋团队在顶级期刊《Nature》上发文，研究发现大脑能够通过“脑-肠轴”通道直接调控肠道的脂肪吸收，同时确定了葛根提取物— 葛根素 ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...

As noted above, stellate cell activation is the central event in hepatic fibrosis. Activation consists of 2 major phases: (1) initiation (also called apreinflammatory stage) and (2) perpetuation ...